Chromogranin A as a biomarker in cardiovascular disease

Biomarkers in Medicine

Volumn 8, Issue 1, 2014, Pages 133-140

  Goetze, Jens P ^a   Alehagen, Urban ^b   Flyvbjerg, Allan ^c   Rehfeld, Jens F ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LINKÖPING UNIVERSITY   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

ANP; BNP; cardiovascular; chromogranin A; heart disease; heart failure; natriuretic peptide

Indexed keywords

BIOLOGICAL MARKER; CATECHOLAMINE; CATESTATIN; CHROMOGRANIN A; CHROMOGRANIN B; EPITOPE; MESSENGER RNA; SECRETOGRANIN II;

BIOLOGICAL ACTIVITY; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CATECHOLAMINE RELEASE; CATECHOLAMINE SYNTHESIS; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; EPITHELIUM CELL; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOCOMPETENT CELL; LUNG DISEASE; NERVE CELL; OBESITY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; REPERFUSION INJURY; REVIEW; RISK FACTOR; RNA TRANSCRIPTION; SMOKING;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHROMOGRANIN A; HUMANS; MYOCARDIUM; RISK FACTORS;

EID: 84890697992     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.102     Document Type: Review

References (66)

1. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N. Engl. J. Med. 348, 1134-1149 (2003
2. Helle KB. Chromogranins A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system. Results Probl. Cell. Differ. 50, 21-44 (2010
3. Parmer RJ, Mahata M, Gong Y et al. Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. J. Clin. Invest. 106, 907-915 (2000
4. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: Progressive retention of immunoreactive fragments. Kidney Int. 37, 955-964 (1990
5. Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J. Clin. Endocrinol. Metab. 78, 1139-1144 (1994
6. Stridsberg M, Öberg K, Li Q, Engström U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J. Endocrinol. 144, 49-59 (1995
7. Tramonti G, Ferdeghini M, Annichiarico C et al. Relationship between renal function and blood level of chromogranin A. Ren. Fail. 23, 449-457 (2001
8. Bech PR, Ramachandran R, Dhillo WS, Martin NM, Bloom SR. Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine-And amphetamine-regulated transcript. Clin. Chem. 58, 941-943 (2012
9. Tateishi K, Funakoshi A, Wakasugi H et al. Plasma pancreastatin-like immunoreactivity in various diseases. J. Clin. Endocrinol. Metab. 69, 1305-1308 (1989
10. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin. Oncol. 39, 410-433 (2012
11. Pasqua T, Corti A, Gentile S et al. Full-length human chromogranin-A cardioactivity: Myocardial, coronary and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts. Endocrinology 154(9), 3353-3365 (2013
12. Corti A, Ferrero E. Chromogranin A and the endothelial barrier function. Curr. Med. Chem. 19, 4051-4058 (2012
13. Angelone T, Mazza R, Cerra MC. Chromogranin-A: A multifaceted cardiovascular role in health and disease. Curr. Med. Chem. 19, 4042-4050 (2012
14. Penna C, Tullio F, Perrelli MG, Mancardi D, Pagliaro P. Cardioprotection against ischemia/reperfusion injury and chromogranin A-derived peptides. Curr. Med. Chem. 19, 4074-4085 (2012
15. Capellino S, Lowin T, Angele P, Falk W, Grifka J, Straub RH. Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus. J. Rheumatol. 35, 91-99 (2008
16. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: Sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 70, 33-45 (1991
17. Takiyyuddin MA, Neumann HP, Cervenka JH et al. Ultradian variations of chromogranin A in humans. Am. J. Physiol. 261, R939-R944 (1991
18. Giampaolo B, Angelica M, Antonio S. Chromogranin 'A' in normal subjects, essential hypertensives and adrenalectomized patients. Clin. Endocrinol. 57, 41-50 (2002
19. Dittadi R, Meo S, Gion M; Italian Committee for the Quality Control in the Oncology Laboratory; Italian Network for Quality Assessment of Tumor Biomarkers. Biological variation of plasma chromogranin A. Clin. Chem. Lab. Med. 42, 109-110 (2004
20. Børglum T, Rehfeld JF, Drivsholm LB, Hilsted L. Processing-independent quantitation of chromogranin A in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas. Clin. Chem. 53, 438-446 (2007
21. Glinicki P, Jeske W. Chromogranin A (CgA)-The influence of various factors in vivo and in vitro, and existing disorders on its concentration in blood. Endokrynol. Pol. 61, 384-387 (2010
22. Sanduleanu S, Stridsberg M, Jonkers D et al. Serum gastrin and chromogranin A during medium-And long-Term acid suppressive therapy: A case-control study. Aliment. Pharmacol. Ther. 13, 145-153 (1999
23. Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-Term proton-pump inhibition. Scand. J. Gastroenterol. 43, 20-24 (2008
24. Håkanson R, Ding XQ, Norlén P, Chen D. Circulating pancreastatin is a marker for the enterochromaffin-like cells of the rat stomach. Gastroenterology 108, 1445-1452 (1995
25. Chen D, Monstein HJ, Nylander AG, Zhao CM, Sundler F, Håkanson R. Acute responses of rat stomach enterochromaffin-like cells to gastrin: Secretory activation and adaptation. Gastroenterology 107, 18-27 (1994
26. Sánchez-Margalet V, Lobón JA, González A, Fernández-Soto ML, Escobar-Jiménez F, Goberna R. Increased plasma pancreastatin-like levels in gestational diabetes: Correlation with catecholamine levels. Diabetes Care 21, 1951-1954 (1998
27. Funakoshi A, Tateishi K, Shinozaki H, Matsumoto M, Wakasugi H. Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM). Regul. Pept. 30, 159-164 (1990
28. Loh YP, Cheng Y, Mahata SK, Corti A, Tota B. Chromogranin A and derived peptides in health and disease. J. Mol. Neurosci. 48, 347-356 (2012
29. Bandyopadhyay GK, Vu CU, Gentile S et al. Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J. Biol. Chem. 287, 23141-23151 (2012
30. Sørhaug S, Langhammer A, Waldum HL, Hveem K, Steinshamn S. Increased serum levels of chromogranin A in male smokers with airway obstruction. Eur. Respir. J. 28, 542-548 (2006
31. Mahapatra NR, O'Connor DT, Vaingankar SM et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J. Clin. Invest. 115, 1942-1952 (2005
32. Friese RS, Altshuler AE, Zhang K et al. MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: Functional and therapeutic implications for gene expression and the pathogenesis of hypertension. Hum. Mol. Genet. 22(18), 3624-3640 (2013
33. Mazza R, Imbrogno S, Tota B. The interplay between chromogranin A-derived peptides and cardiac natriuretic peptides in cardioprotection against catecholamine-evoked stress. Regul. Pept. 165, 86-94 (2010
34. Sahu BS, Sonawane PJ, Mahapatra NR. Chromogranin A: A novel susceptibility gene for essential hypertension. Cell. Mol. Life. Sci. 67, 861-874 (2010
35. Di Comite G, Morganti A. Chromogranin A: A novel factor acting at the cross road between the neuroendocrine and the cardiovascular systems. J. Hypertens. 29, 409-414 (2011
36. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JA, Parmer RJ, O'Connor DT. Chromogranin A. Storage and release in hypertension. Hypertension 15, 237-246 (1990
37. Steiner HJ, Weiler R, Ludescher C, Schmid KW, Winkler H. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J. Histochem. Cytochem. 38, 845-850 (1990
38. Glattard E, Angelone T, Strub JM et al. Characterization of natural vasostatin-containing peptides in rat heart. FEBS J. 273, 3311-3321 (2006
39. Pieroni M, Corti A, Tota B et al. Myocardial production of chromogranin A in human heart: A new regulatory peptide of cardiac function. Eur. Heart J. 28, 1117-1127 (2007
40. Wohlschlaeger J, von Winterfeld M, Milting H et al. Decreased myocardial chromogranin A expression and colocalization with brain natriuretic peptide during reverse cardiac remodeling after ventricular unloading. J. Heart Lung Transplant. 27, 442-449 (2008
41. Biswas N, Curello E, O'Connor DT, Mahata SK. Chromogranin/secretogranin proteins in murine heart: Myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell Tissue Res. 342, 353-361 (2010
42. Costello-Boerrigter LC, Burnett JC Jr. The prognostic value of N-Terminal pro-B-Type natriuretic peptide. Nat. Clin. Pract. Cardiovasc. Med. 2, 194-201 (2005
43. Omland T, Dickstein K, Syversen U. Association between plasma chromogranin A concentration and long-Term mortality after myocardial infarction. Am. J. Med. 114, 25-30 (2003
44. Estensen ME, Hognestad A, Syversen U et al. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am. Heart J. 152, 927.e1-e6 (2006
45. Jansson AM, Røsjø H, Omland T et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur. Heart J. 30, 25-32 (2009
46. Wang X, Xu S, Liang Y et al. Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction. Biomarkers 16, 372-377 (2011
47. Ferraro S, Ardoino I, Boracchi P et al. Inside ST-elevation myocardial infarction by monitoring concentrations of cardiovascular risk biomarkers in blood. Clin. Chim. Acta 413, 888-893 (2012
48. Manhenke C, Orn S, von Haehling S et al. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int. J. Cardiol. 166(3), 729-735 (2011
49. Jiang Q, Taupenot L, Mahata SK et al. Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J. Biol. Chem. 276, 25022-25029 (2001
50. Colombo B, Longhi R, Marinzi C et al. Cleavage of chromogranin A N-Terminal domain by plasmin provides a new mechanism for regulating cell adhesion. J. Biol. Chem. 277, 45911-45919 (2002
51. Biswas N, Vaingankar SM, Mahata M et al. Proteolytic cleavage of human chromogranin A containing naturally occurring catestatin variants: Differential processing at catestatin region by plasmin. Endocrinology 149, 749-757 (2008
52. Crippa L, Bianco M, Colombo B et al. A new chromogranin A-dependent angiogenic switch activated by thrombin. Blood 121, 392-1402 (2013
53. Braunwald E. Biomarkers in heart failure. N. Engl. J. Med. 358, 2148-2159 (2008
54. Corti A, Ferrari R, Ceconi C. Chromogranin A and tumor necrosis factor-A (TNF) in chronic heart failure. Adv. Exp. Med. Biol. 482, 351-359 (2000
55. Ceconi C, Ferrari R, Bachetti T et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur. Heart J. 23, 967-974 (2002
56. Boriani G, Regoli F, Saporito D et al. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response. Peptides 27, 1776-1786 (2006
57. Dieplinger B, Gegenhuber A, Struck J et al. Chromogranin A and C-Terminal endothelin-1 precursor fragment add independent prognostic information to amino-Terminal proBNP in patients with acute destabilized heart failure. Clin. Chim. Acta 400, 91-96 (2009
58. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95, 1508-1513 (2009
59. Røsjø H, Masson S, Latini R et al.; GISSI-HF Investigators. Prognostic value of chromogranin A in chronic heart failure: Data from the GISSI-Heart Failure trial. Eur. J. Heart Fail. 12, 549-556 (2010
60. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin. Biochem. 43, 714-719 (2010
61. Zhu D, Wang F, Yu H, Mi L, Gao W. Catestatin is useful in detecting patients with stage B heart failure. Biomarkers 16, 691-697 (2011
62. Gadroy P, Stridsberg M, Capon C et al. Phosphorylation and O-glycosylation sites of human chromogranin A (CGA79-439) from urine of patients with carcinoid tumors. J. Biol. Chem. 273, 34087-34097 (1998
63. Bardram L, Rehfeld JF. Processing-independent radioimmunoanalysis: A general analytical principle applied to progastrin and its products. Anal. Biochem. 175, 537-543 (1988
64. Jensen TB, Hilsted L, Rehfeld JF. Library of sequence-specific radioimmunoassays for human chromogranin A. Clin. Chem. 45, 549-560 (1999
65. Rehfeld JF, Goetze JP. The posttranslational phase of gene expression: New possibilities in molecular diagnosis. Curr. Mol. Med. 3, 25-38 (2003
66. Goetze JP, Hunter I, Lippert SK, Bardram L, Rehfeld JF. Processing-independent analysis of peptide hormones and prohormones in plasma. Front. Biosci. 17, 1804-1815 (2012